The answer is simple. Corruption. The change to 700mg was simply a delay tactic. Hopefully, no more delays, but I am extremely skeptical of any approval from the FDA.
After FDA asked us the last time for efficacy and safety of ALL over 500 patients from monotherapy , this only makes sense if they planning to approve mono and combo..and this is the only reason delay will be worth...
If they don't , I don't know what options shareholders will have , but we should send some complains to higher instances ...because it is worse then any of us could imagine ...
Birddogfishman.. To be honest..The FDA realized that once Leronlimab was given as a combo..Physicians would likely dump the OTHER drugs...Why risk their potential side effects..with NO BENEFIT to boot..?? So in a sense.. approving Leronlimab as a combo..would have been analogous to approving it as a MONOTHERAPY..If that be the case..Would 700mg be better..??
Market Data 
Markets 
AI
